Cyclin-dependent kinase inhibitors as marketed anticancer drugs: where are we now? A short survey.

  title={Cyclin-dependent kinase inhibitors as marketed anticancer drugs: where are we now? A short survey.},
  author={Ga{\"e}lle Mariaule and Philippe Belmont},
  volume={19 9},
In the early 2000s, the anticancer drug imatinib (Glivec®) appeared on the market, exhibiting a new mode of action by selective kinase inhibition. Consequently, kinases became a validated therapeutic target, paving the way for further developments. Although these kinases have been thoroughly studied, none of the compounds commercialized since then target cyclin-dependent kinases (CDKs). Following a recent and detailed review on the subject by Galons et al., we concentrate our attention on an… CONTINUE READING
Highly Cited
This paper has 190 citations. REVIEW CITATIONS

From This Paper

Figures, tables, and topics from this paper.

Explore Further: Topics Discussed in This Paper


Publications citing this paper.
Showing 1-10 of 23 extracted citations

CDK9 inhibitors in acute myeloid leukemia

Journal of experimental & clinical cancer research : CR • 2018
View 1 Excerpt

191 Citations

Citations per Year
Semantic Scholar estimates that this publication has 191 citations based on the available data.

See our FAQ for additional information.


Publications referenced by this paper.
Showing 1-10 of 63 references

LEE011 CDK Inhibitor Showing Early Promise in Drug-Resistant Cancers

S. Kurt
Oncol. Times 2014, • 2014
View 10 Excerpts
Highly Influenced

Targeting Protein Kinases for Cancer Therapy

D. J. Matthews, M. E. Gerritsen
View 8 Excerpts
Highly Influenced

Cyclin-dependent kinase inhibitors closer to market launch?

Expert opinion on therapeutic patents • 2013
View 4 Excerpts
Highly Influenced

Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2010
View 3 Excerpts
Highly Influenced

A phase II study of milciclib (PHA-848125AC) in patients with thymic carcinoma

B. Besse, M. C. Garassino, +7 authors C Davite
In Proceedings of the American Society of Clinical Oncology Conference, • 2014
View 2 Excerpts

Blockbuster dreams for Pfizer's CDK inhibitor

Nature Biotechnology • 2013
View 1 Excerpt

Similar Papers

Loading similar papers…